Adithi Kellarai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adithi Kellarai has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Uday Venkat Mateti
Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (Deemed to be University), Mangalore, Karnataka, India
2 shared publications - Amna Reem M. A.1 shared publication
Anjana Madhusoodanan
1 shared publicationAnu Sunny
1 shared publicationShaikh Rafiya Rafikahmed
1 shared publication- Shailaja S. Moodithaya
Department of Physiology, KS Hegde Medical Academy (KSHEMA), Nitte (Deemed to be University), Deralakatte, Mangaluru, Karnataka, India
1 shared publication
Latest Publications
- Open Access
- 3 July 2026
- Published by SAGE Publications in Journal of Applied Pharmaceutical Science
A Cross-sectional Study to Assess the Distress Among Type II Diabetes Mellitus Patients: A Regional Adaptation of PAID-20 Scale
Diabetic distress remains underreported, with its incidence and prevalence varying across regions and lacking consistent documentation. Furthermore, routine clinical practice rarely incorporates standardized assessment of this form of distress. Therefore, we aimed to translate, validate, and test the reliability of the Problem Areas in Diabetes (PAID)-20 scale into two regional languages, Malayalam and Kannada, and evaluate the diabetes-associated distress and its association with glycaemic control and sociodemographic factors among patients with type 2 diabetes mellitus (DM). Following validation, both the scales were administered to assess distress scores and their association with patients’ sociodemographic and clinical parameters. Further, the validated scales were found to be reliable for their regional use (Cronbach- α > 0.7). A cross-sectional study was conducted among 354 patients with type 2 DM at a tertiary care hospital; males (63.84%) were predominant over females (36.16%), with the overall mean age of 61.1 ± 10.25 years. The prevalence of diabetes-related distress was 28.8%, with a weak positive correlation between glycated hemoglobin (HbA1c) levels and diabetes-related distress, which was statistically significant ( r = 0.141, p = .008), indicating that poorer glycemic control is associated with higher distress. Further, family history of diabetes and socioeconomic status were found to have a marginally significant association with distress level among diabetes patients ( p = .059 and p = .055). Routine assessment of diabetes distress using these regionally adapted tools may facilitate clinical and psychological diabetes management.
- 3 July 2026
- Published by SAGE Publications in Journal of Applied Pharmaceutical Science
Open AccessA Cross-sectional Study to Assess the Distress Among Type II Diabetes Mellitus Patients: A Regional Adaptation of PAID-20 Scale
Diabetic distress remains underreported, with its incidence and prevalence varying across regions and lacking consistent documentation. Furthermore, routine clinical practice rarely incorporates standardized assessment of this form of distress. Therefore, we aimed to translate, validate, and test the reliability of the Problem Areas in Diabetes (PAID)-20 scale into two regional languages, Malayalam and Kannada, and evaluate the diabetes-associated distress and its association with glycaemic control and sociodemographic factors among patients with type 2 diabetes mellitus (DM). Following validation, both the scales were administered to assess distress scores and their association with patients’ sociodemographic and clinical parameters. Further, the validated scales were found to be reliable for their regional use (Cronbach- α > 0.7). A cross-sectional study was conducted among 354 patients with type 2 DM at a tertiary care hospital; males (63.84%) were predominant over females (36.16%), with the overall mean age of 61.1 ± 10.25 years. The prevalence of diabetes-related distress was 28.8%, with a weak positive correlation between glycated hemoglobin (HbA1c) levels and diabetes-related distress, which was statistically significant ( r = 0.141, p = .008), indicating that poorer glycemic control is associated with higher distress. Further, family history of diabetes and socioeconomic status were found to have a marginally significant association with distress level among diabetes patients ( p = .059 and p = .055). Routine assessment of diabetes distress using these regionally adapted tools may facilitate clinical and psychological diabetes management.
- Open Access
- 31 December 2023
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 16 (4) , 2419-2424
Cardio-Metabolic Indices in Relation to Serum Vitamin D Levels among Middle-Aged Adults
Biomedical and Pharmacology Journal (BPJ) is an international, open access, peer reviewed, quarterly research journal.
- 31 December 2023
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 16 (4) , 2419-2424
Open AccessCardio-Metabolic Indices in Relation to Serum Vitamin D Levels among Middle-Aged Adults
Biomedical and Pharmacology Journal (BPJ) is an international, open access, peer reviewed, quarterly research journal.
- Open Access
- 1 October 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2200118
Comprehensive Review of Hepatocellular Carcinoma in India: Current Challenges and Future Directions
There is not much information on hepatocellular carcinoma (HCC) in India. Here, we review the existing data, available treatment choices, and future directions in HCC management. An extensive search was conducted through PubMed and MEDLINE for studies published between January 2000 and June 2022 on the epidemiology of HCC in India using the following key words: atezolizumab, BCLC staging, hepatocellular carcinoma, immune checkpoint inhibitors, immunotherapy, and programmed cell death ligand-1, with the filters humans and English language. The most frequent risk factors for the development of HCC in India include nonalcoholic fatty liver disease, hepatitis B virus and hepatitis C virus infection, liver cirrhosis, and alcohol intake. On the basis of new findings, the Barcelona Clinic Liver Cancer (BCLC) Staging Criteria need to be revised. As most cases in India are discovered at a later stage, curative treatments such as surgical resection, ablation, or liver transplantation may not be an option. Clinical trials are underway for a number of immune checkpoint drugs that target cytotoxic T-cell lymphocyte-4 and programmed cell death-1/programmed cell death-ligand 1. In India, phase III trials of atezolizumab in combination with other drugs are underway for the treatment of various malignancies. Renin angiotensin system inhibitors, antivirals, primary hepatocyte transplantation, and bioartificial liver devices are among the future options for the management of HCC. In developing countries like India, HCC is often diagnosed at an advanced stage because of a delay in routine testing or screening. Therefore, developing effective treatment regimens for such stages is critical. Immunotherapy is a promising treatment option that has the potential to increase overall response and survival rate.
- 1 October 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2200118
Open AccessComprehensive Review of Hepatocellular Carcinoma in India: Current Challenges and Future Directions
There is not much information on hepatocellular carcinoma (HCC) in India. Here, we review the existing data, available treatment choices, and future directions in HCC management. An extensive search was conducted through PubMed and MEDLINE for studies published between January 2000 and June 2022 on the epidemiology of HCC in India using the following key words: atezolizumab, BCLC staging, hepatocellular carcinoma, immune checkpoint inhibitors, immunotherapy, and programmed cell death ligand-1, with the filters humans and English language. The most frequent risk factors for the development of HCC in India include nonalcoholic fatty liver disease, hepatitis B virus and hepatitis C virus infection, liver cirrhosis, and alcohol intake. On the basis of new findings, the Barcelona Clinic Liver Cancer (BCLC) Staging Criteria need to be revised. As most cases in India are discovered at a later stage, curative treatments such as surgical resection, ablation, or liver transplantation may not be an option. Clinical trials are underway for a number of immune checkpoint drugs that target cytotoxic T-cell lymphocyte-4 and programmed cell death-1/programmed cell death-ligand 1. In India, phase III trials of atezolizumab in combination with other drugs are underway for the treatment of various malignancies. Renin angiotensin system inhibitors, antivirals, primary hepatocyte transplantation, and bioartificial liver devices are among the future options for the management of HCC. In developing countries like India, HCC is often diagnosed at an advanced stage because of a delay in routine testing or screening. Therefore, developing effective treatment regimens for such stages is critical. Immunotherapy is a promising treatment option that has the potential to increase overall response and survival rate.
- Open Access
- 1 October 2021
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 12
Knowledge, attitude, and practice on insulin administration among diabetic patients and their caregivers – Cross-sectional study
- 1 October 2021
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 12
Open AccessKnowledge, attitude, and practice on insulin administration among diabetic patients and their caregivers – Cross-sectional study